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Summary
Purpose: To evaluate the efficacy and tolerability of Levetiracetam as an add-on
therapy in patients with startle epilepsy (StEp).
Methods: Ten (7 males and 3 females) were enrolled in the study. LEV was started at
500 mg bid, escalating over 1—2 weeks to maximal doses of 3000 mg daily, based on
seizure control and tolerance for 13—28 months.
Results: The onset of startle seizures in patients with StEp varied from birth to 11
years. Six in 10 patients gave good responses to the treatment. There were adverse
effects in three patients.
Conclusion: Many AEDs have been used by medically intractable patients with StEp
for many years but the results were almost discouraging.
It was observed that 60% of the patients gave good response to LEV. Advanced
studies are required to indicate the efficiency of LEV which proved to be effective on
animals with audiogenic seizures on reflex epilepsies.
# 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Startle epilepsy (StEp) was first described in 1955.1
It is mostly seen in patients with static or progressive
encephalopathy in addition to comparatively fewer
clinically normal cases.2—5 Among the etiological* Corresponding author. Tel.: +90 212 4142000/32565;
fax: +90 212 5334393.
E-mail address: candan.gurses@gmail.com (C. Gu¨rses).
1059-1311/$ — see front matter # 2008 British Epilepsy Association
doi:10.1016/j.seizure.2008.04.003causes are perinatal anoxia, stroke, Sturge—Weber
syndrome, porencephalic cyst, postinflammatuar
changes, dysplastic lesions, Down syndrome and
familial neonatal convulsions. The insult typically
occurs within the first 2 years of life and is often pre-
or perinatal. The onset of StEp is in childhood or
early adolescence. StEp is a well-defined clinical
condition related to above-mentioned early lesions
of the motor cortex. Neuroimaging findings can be
normal, or it may show localized or diffuse lesions.
The lateralized lesions usually involve sensorimotor. Published by Elsevier Ltd. All rights reserved.
626 C. Gu¨rses et al.and premotor cortex, and white matter. Focal or
generalized atrophy is reported.6 There are a few
case reports or papers on groups of limited number
of patients with StEp. The treatment of StEp is not
always successful because total control of seizures is
nearly impossible. The prognosis is usually bad espe-
cially in patients with preexisting severe encepha-
lopathies. Because of the scarcity of patients with
StEp, drug trials involving only a few patients could
be done.2,3,7
Levetiracetam (LEV) is well tolerated with favor-
able pharmacokinetic profile that includes minimal
protein binding, lack of hepatic metabolism and
twice a day dosing.8—12
In this study our aim is to evaluate prospectively
the efficacy and tolerability of LEV as an add-on
therapy in patients with StEp.Patients and methods
Out of 7759 patients, thirty with seizures triggered
by unexpected stimulus have been diagnosed as StEp
in Epilepsy Outpatient Clinic of Neurology Depart-
ment since 1979. Only thirteen of 30 patients could
be followed since only they came for their controls
regularly while the others showed up either rarely or
never for their follow-ups. The patients’ files are
reviewed with respect to their personal history, the
onset of seizures (startle and spontaneous), fre-
quency of seizures, provoking factors, neurological
examination, mental retardation, neuroradiological
findings, previously and currently used antiepileptic
drugs (AEDs), responses of their spontaneous and
startle seizures to LEV. Only 3 of 13 patients had
good control seizure, i.e. they had no more startle
seizures but only a few spontaneous seizures. They
had no differences from the patients with intract-
able startle epilepsy in terms of the above-men-
tioned risk factors. The seizures of the other 10
patients were difficult to control despite the regular
use of adequate AEDs. To test IQ, Alexander, Good
enough and Cattell IQ tests are preferred to Wechs-
ler Adult Intelligence Scale (WAIS) test since the
latter has not been standardized for Turkish popula-
tion. All patients were tested with only 1 of the
three tests when applicable.
Their seizure diaries had been kept either by
themselves or their families for 2 months before
LEV treatment. They were included in the study to
receive LEV treatment as an add-on therapy. LEV
was started at 500 mg bid, escalating over 1—2
weeks to maximal doses of 3000 mg daily, based
on seizure control and tolerance for 13—28 months.
Patients had used upto 7 types of AEDs separately
and during the study they used 1 to 3 types of AEDssimultaneously in addition to LEV. The dosage was
adjusted individually for each patient with startle
epilepsy. Visits were planned to be every 4 weeks, by
alternating visits to hospital or calling the patient
from home.
All patients and/or their parents gave written
informed consent to the study which was done with-
out both any specific funding and the involvement of
any pharmaceutical company.Results
There are 7 males and 3 females in our study group.
The mean age of the patients is 26.93  3.87 (21—
34). In their previous history of the patients, birth
hypoxia in 4, head trauma in 2, meningitis in 1,
perinatal stroke in 1, prolonged birth and small
gestational age in 1, subdural and intraventricular
hematoma in 1, febrile or nonfebrile convulsion in 2
were found. Febrile and nonfebrile convulsions did
not recur until the onset age of seizures. They had
no previous histories of status epilepticus.
The onset of startle seizures in patients with StEp
varied from birth to 11 years. The mean onset of age
of epilepsy was 5.0  4.71 years and the mean
duration of epilepsy was 21.9  5.82 years. The
patients had two types of seizures, startle and
spontaneous; both with the same characteristics:
7 patients had tonic seizures, 5 of whose were
asymmetrical tonic. One patient had left focal
motor seizures and 2 had partial and/or secondary
generalized seizures in addition to their startle
seizures. Themain triggering stimuli for their startle
seizures were sudden sound, found in all the
patients, followed by touching or hitting any part
of their bodies. The stimuli were sudden sounds in 10
patients, touching and sound in 7, stumbling in 2,
fear, pain, excitement or scary dreams in 3 (Table 1).
Both startle and spontaneous seizures were seen in
patients with StEp while spontaneous ones were
rare.
Abnormality was found in 9 patients in their
neurological examination, the most common find-
ings being hemiparesis with hyperactive reflexes
and an extensor plantar response in 50%.
Due to the diverse features of the patients,
different IQ tests were performed for each. The
mentally retarded and borderline IQ patients con-
stituted 70% of the group.
4 of the patients were mentally retarded, (3
(30%) severe, 1 (10%) moderate) and 3 (30%) had
borderline IQ. It was not required to measure the IQ
of 2 patients who were clinically normal.
Magnetic resonance imaging (MRI) showed
abnormality in 8 patients. The abnormal MRI findings
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Table 1 Clinical and treatment data of the patients with Startle Epilepsy
Pt no. Age/sex Onset
age of
epilepsy
Personal
history
Triggering
stimulus
Seizure
type
MenRet NE Neuroradiology
1 27/M 1 month Intraventricular
and subdural
hematoma,
operated when
1 month old
Door bell Tonic jerks on
the right arm-leg
followed by falls
Alexander 68,
borderline IQ
Right spastic hemiparesis
and growth asymmetry on
the right arm, hyperactive
deep tendon reflexes on
the right, extensor right
plantar reflex
Hypoplasia in the left
hemisphere, third
ventricular dilatation
and cystic lesion beginning
from left frontal horn to
occipital horn and skull
defect due to operation
2 26/F 9 years Prolonged
birth, SGA
(1500 g), clonic
jerks on the
right arm once
when 40 days old
Stumbling
sudden
sound
Hypoesthesia on
the right arm,
staring and being
unable to speak
Alexander 84
borderline IQ
Frust right hemiparesis Posterior horn dilatation
over the left hemisphere
and temporo-parietal
cortical encephalomalacia
3 27/F 9 years - Sudden
sound and
touching
Asymmetric tonic
beginning with
left leg
Not required Normal, cooperated well,
no intellectual deficit
Normal
4 21/M Birth Birth hypoxia Stumbling with
right foot,
sudden sound,
fear
Tonic Severe, unable
to perform in
the test
Comprehension difficulty,
unable to perform
commands with two or
more steps
Bilateral periventricular
gliosis with significant
extension into cortical and
subcortical deep white
matter especially in the
parietooccipital region
5 34/M 7 years Meningitis when
2 years old
Sudden sound,
touching and
excitement
Mostly asymmetrical
tonic on the left,
sometimes bilateral
Severe, unable to
perform in the test
Bilateral hyperactive DTR,
bilateral extensor
plantar responses
High signal intensities
in the periventricular
white matter
predominantly in the
right frontal periventricular
region and bilateral
frontal atrophy
6 25/M 13 years Right-sided
perinatal
stroke
Sudden sound
and touching
Asymmetrical tonic Not done Right spastic hemiparesis,
extensor right plantar reflex
infarct in the left middle
cerebral artery including
lentiform nucleus
7 29/M 1 year Birth hypoxia Sudden sound,
touching
and pain
Sudden staring
followed by
falling back with
a rigid posture
Alexander 83
borderline
Logoreic speech High intensity in the
periventricular WM,
distinct atrophy in the
sylvian fissure and opercular
cortical region and areas
of ulegyria
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Table 1 (Continued )
Pt no. Age/sex Onset
age of
epilepsy
Personal
history
Triggering
stimulus
Seizure
type
MenRet NE Neuroradiology
8 31/M 1 year Birth hypoxia Sudden sound
and touching
Asymmetric tonic
in the left leg
Alexander 44
moderate
Bilateral optic atrophy,
frust left hemiparesis,
hyperactive deep tendon
reflexes on the left,
extensor left plantar reflexes
High intensity in the
periventricular WM
more prominent over
bioccipital regions
9 22/M 2 years Birth hypoxia Sudden touching
and sound of horn
Clonic jerks on
the left arm and
leg followed by falls
Severe, unable to
perform in the test
Spastic and ataxic
quadriparesis, bilateral
hyperactive deep tendon
reflexes, extensor
bilateral plantar reflexes
Bilateral cerebral
atrophy, along with
Periventricular WM
intensities prominent
over bioccipital regions
10 27/F 8 years Fell from 2 m high
when 2 years old,
without LOC
Sudden sound and
touching, scary
dreams
Tonic jerks in the
right arm and leg
Not required Normal mental functioning,
Frust right hemiparesis,
Normal
Pt no. Previously
used AEDs
No. of AEDs used
except LEV
Spont s
before LEV
Startle s
before LEV
Spont s
after LEV
Startle s
after LEV
LEV maintenance
dosage (day)
Adverse
effects of LEV
Follow-up
(month)
1 VPA, CBZ VPA 500 mg/day — Everyday or
once in 3 days
— Everyday 500 mg — Quit after 2 mos
2 CBZ, VPA, VGB CBZ 1200 — 5—6/d — 2500 mg Nervousness,
forgetfulness
24
3 PB, VPA, CBZ PB 200 1—3/m 1—2/d — — 2000 mg — 26
4 PB, CBZ, OXC, LMT OXC1200,
LMT200, PB100
— 8—10/d — 3—4/d 2000 Dizziness Quit after 2 mos
5 CBZ, PB CBZ1000 — 5—6/d — 10—12/d — Quit after 2 mos
6 OXC, TPM, LMT, VPA,
CLB, CLZ, CBZ
OXC900, TPM1200 10—15/m 50—60/m 10—15/m 1/m 2000 mg — 28 mo
7 CBZ, LMT, VPA, PB CBZ 1200, LMT 400 10—15/m 2—10/m — 6—7/m — 25 mo
8 CBZ, VPA, LMT CBZ 1000 — 2—3/d — 0—1/d 1000 mg Agitation Quit after 1 mos
9 CBZ, CLO, PB, PHT CBZ 400, PB100 Once in
every 1—2 mos
Countless — — — 22 mo
10 PB, CBZ, VPA CBZ 1000, VPA600 2—3/m 12/m 2—3/m 20/m 250 mg — Quit after 2 mo
AED, antiepileptic drug; CBZ, carbamazepin; CLO, clonazepam; d, day; do, day-old; DTR, deep tendon reflex; F, female; IQ, Intelligence Quotient; yo, year-old; LEV, levetiracetam; LOC, loss
of consciousness; LMT, lamotrgine; M,male; mo,month-old; MenRet, mental retardation;m,month; NE, neurological examination; OXC, oxcarbazepin; PB, Phenobarbital; PHT, phenytoin; Pt,
patient; SGA, small gestational age; Spont., spontaneous seizure; Startle s, startle seizure; TPM, topiramate; VPA, vaplroat; WM, white matter.
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periventricular region to bilateral periventricular
gliosis with significant extension into cortical and
subcortical deep white matter especially in the
parietooccipital region, all of which can be defined
as periventricular leukomalacia. Among the other
MRI findings, there were left middle cerebral artery
infarct in 1, hypoplasia in the left hemisphere, third
ventricular dilatation and cystic lesion beginning
from left frontal horn to occipital horn and skull
defect due to operation in 1, and the other 2
patients displayed no abnormalities.
EEG abnormalities were seen in all 10 patients. In
the EEGs recorded during their follow-up, the most
frequent findings were abnormal background activ-
ity in 9, epileptiform discharges in 3 and non-epi-
leptiform discharges in 4.
The frequency of spontaneous seizures ranged
from 1 to 15 a month before LEV and the frequency
of their startle seizures varied from 20 to countless
number of seizures per month before LEV in 10
patients with StEp. The average dose of LEV in
patients was 1916.66  861.20 (500—3000) mg.
The average follow-up period was 22.66  5.50
(12—28) months. Average numbers of monthly sei-
zures as well as the distributions of AEDs used
before and during LEV treatment are shown in
Table 1. Five of the patients had no spontaneous
seizures also before LEV. The response rates in
spontaneous seizures were 100% in 3 and no change
in 2 after LEV. With respect to their startle sei-
zures, 3 (30%) of the patients were seizure free, 3
(30%) had 50—90% seizure decrease, 1 (10%) had
25—50% seizure decrease, and 3 (30%) had seizure
increase.
Six in 10 patients (60%) gave good responses to
the treatment. In 3 patients, on the other hand, the
frequency of seizures increased and in 1 the drug
was somewhat ineffective on startle seizures. There
were adverse effects in 3 patients. Although 50%
decrease in the frequency of startle seizures was
observed, LEV was discontinued in 1 of the mentally
retarded patients (Case 8) due to agitation. The
family of the other mentally retarded patient (Case
4) who felt dizziness stopped him from using the
drug despite the decrease in the number of his
seizures. The patient (Case 2) who complained from
nervousness and forgetfulness was seizure free after
many years. Therefore, she did not want to with-
draw the drug. When the MRI findings are consid-
ered, no difference with respect to their responses
to LEV is found between mild and severe abnorm-
alities in terms of periventricular leukomalacia in
6 patients.
Mental retardation was not thought to be a wor-
sening factor in terms of response to LEV.Discussion
We were discouraged by our former experience of
trying to take seizures under control in our patients
with startle epilepsy especially when the high num-
ber of previously and currently used AEDs were
considered along with the information in literature.
However, most of our cases with either periven-
tricular leukomalacia or motor cortex lesions as well
as mental retardation have potential risk for intract-
ability of the treatment even without considering
the fact that they have startle seizures.
The low number of patients in the series studies
hindered the possibilities of controlled studies on
startle epilepsy. In a study about the effectiveness
of Clonazepam, the drug proved to have good sei-
zure control for a certain period of time but the
seizures recurred afterwards.13 Another study about
the effects of Clobazam showed that it obtained
good control of seizures over a 22.75 months per-
iod.2 Lamotrigine therapy was also shown to have
good effects on patients with startle epilepsy.7
LEV is a comparatively new AED which is rapidly
and almost completely absorbed after oral admin-
istration. After 2 days of twice–—daily dosing, steady
state plasma levels are achieved. The elimination
route of LEV is in the urine. LEV is <%10 protein
bound and does not appear to interact with other
drugs. These characteristics of LEV make it prefer-
able among the other possible AEDs. The absence of
drug interaction in LEV treatment is its other advan-
tage for patients who use many AEDs. LEV is well
tolerated, with adverse effects such as somnolance,
asthenia, coordination difficulties or behavioral
symptoms.8—12 Our patients received LEV treatment
for periods of 12—28 months. In 3 of our patients
(30%) adverse effects were observed and 1 of them
discontinued the drug because of agitation.
It was observed that 60% of the patients gave
good response to the treatment. These patients
maintained their good seizure control over the fol-
lowing months. It is difficult to predict whether the
positive effects of LEV on seizure control will be
preserved in the following years. However, it is a
well-known fact that the effectiveness of AEDs
decreases in time in patients with intractable epi-
lepsy.
One important factor to consider in our patients
was their being either mentally retarded or having
borderline IQs. Therefore low good response rates
could be expected from our patients, but no differ-
ence in terms of seizure control between them
and the clinically normal patients was observed.
There are two studies conducted on mentally
retarded patients with epilepsy, which also convey
no difference with respect to their becoming seizure
630 C. Gu¨rses et al.free: 38—40% of the patients in both groups were
seizure free.14,15 However, another study elucidated
that mentally retarded patients and/or patients
with behavioral problems showed more adverse
effects.16
LEV anticonvulsant activity was discovered in
audiogenic seizure. LEV inhibited audiogenic-
induced tonic and clonic convulsions in audiogenic
seizure sensitive mice17 and rats.18 Although the
pathophysiologicalmechanismofaudiogenic seizures
is different from startle epilepsy, they are important
for being reflex seizures responsive to LEV.
Investigating reflex seizures further with human
and animal experiences is important to illuminate
the effect mechanisms of LEV, that is not well
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